Zolentra (Zoledronic Acid)
800 mcg/mL (4 mg/5 mL)
Concentrated Solution for Injection IV
Biphosphonate
INDICATION
Treatment of osteoporosis (annual IV therapy), Paget’s disease of bone, hypercalcemia of malignancy, prevention/treatment of skeletal-related events from bone metastases and multiple myeloma.
PHARMACODYNAMICS
Absorption: IV → essentially 100% bioavailability.
Distribution: Rapid uptake into bone with high affinity for hydroxyapatite; low plasma volume of distribution.
Metabolism: Not metabolized.
Elimination: Renal excretion of unchanged drug; large portion rapidly deposited in bone and retained long-term.
Protein Binding: Low (relatively limited plasma protein binding).
Half Life: Rapid plasma/distribution half-life (hours); terminal skeletal half-life prolonged (months–years due to bone binding).
MECHANISM OF ACTION
Inhibits farnesyl diphosphate synthase (mevalonate pathway) in osteoclasts → impairs prenylation, induces osteoclast apoptosis and inhibits bone resorption
PHARMACODYNAMICS
Reduces bone resorption and serum calcium, increases bone mineral density, reduces risk of fractures and skeletal-related events in malignancy.
CAUTION:
Renal impairment (avoid or adjust if eGFR/CrCl markedly reduced), baseline hypocalcemia (correct before therapy), pregnancy/lactation, risk of osteonecrosis of the jaw (ONJ), atypical femoral fractures, acute phase reactions, atrial fibrillation risk in some studies
OVERDOSE AND TREATMENT
Overdose → prolonged hypocalcemia and renal toxicity. Management supportive: monitor renal function and electrolytes, IV calcium for symptomatic hypocalcemia, aggressive hydration, consider nephrology support. Dialysis has limited utility once drug is bone-bound.
PREGNANCY AND LACTATION
Avoid in pregnancy (potential fetal harm due to effects on fetal bone). Use only if clearly necessary. Not recommended during breastfeeding (excreted/retained in bone; risk unknown) — generally avoid.
METHOD OF ADMINISTRATION
IV infusion only. Typical practice: dilute and administer as single IV infusion over at least 15 minutes (ensure adequate hydration; correct hypocalcemia prior). Use dosing regimen appropriate to indication.
TOXICITY
Acute phase reactions (fever, myalgia), hypocalcemia, renal impairment/acute kidney injury, ONJ, atypical femoral fractures, ocular inflammation, possible atrial fibrillation.
DOSAGE RECOMMENDATION:
Osteoporosis: 5 mg IV once yearly (note: product strength you specified is 4 mg; 4 mg is commonly used for oncology indications).
Hypercalcemia of malignancy: single 4 mg IV infusion (dose regimens vary).
Bone metastases/multiple myeloma: 4 mg IV every 3–4 weeks (adjust/hold for renal impairment). Always follow local product labeling for exact dose/interval and renal thresholds.
WHY ZOLENTRA?
Once-yearly IV dosing improves adherence vs daily/weekly oral bisphosphonates.
Avoids GI irritation/oesophagitis associated with oral bisphosphonates.
Greater potency and shorter infusion time compared with older IV bisphosphonate (pamidronate) and effective at lower volume/frequency for many oncology indications.
